ShanmugasundaramMRamVKLuftUC. Peripheral arterial disease—what do we need to know?Clin Cardiol. 2011;34:478–482.
2.
ShishehborMHWhiteCJGrayBH. Critical limb ischemia: an expert statement. J Am Coll Cardiol. 2016;68:2002–2015.
3.
FagliaEClericiGScatenaA. Severity of demographic and clinical characteristics, revascularization feasibility, major amputation, and mortality rate in diabetic patients admitted to a tertiary diabetic foot center for critical limb ischemia: comparison of 2 cohorts recruited at a 10-year distance. Ann Vasc Surg. 2014;28:1729–1736.
4.
NevilleRFLidskyMCaponeA. An expanded series of distal bypass using the distal vein patch technique to improve prosthetic graft performance in critical limb ischemia. Eur J Vasc Endovasc Surg. 2012;44:177–182.
5.
AdamDJBeardJDClevelandT; BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–1934.
6.
MenardMTFarberAAssmannSF. Design and rationale of the best endovascular versus best surgical therapy for patients with critical limb ischemia (BEST-CLI) Trial. J Am Heart Assoc. 2016;5:e003219.
7.
Biondi-ZoccaiG.Why interventional cardiologists may be the most suitable specialists for the endovascular management of peripheral artery disease. Minerva Cardioangiol. 2013;61:367–370.
8.
Biondi-ZoccaiGGAgostoniPSangiorgiG. Mastering the antegrade femoral artery access in patients with symptomatic lower limb ischemia: learning curve, complications, and technical tips and tricks. Catheter Cardiovasc Interv. 2006;68:835–842.
9.
AiroldiFFagliaELosaS. Antegrade approach for percutaneous interventions of ostial superficial femoral artery: outcomes from a prospective series of diabetic patients presenting with critical limb ischemia. Cardiovasc Revasc Med. 2012;13:20–24.
10.
FagliaEManteroMCaminitiM. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. J Intern Med. 2002;252:225–232.
11.
ShishehborMHJaffMR.Percutaneous therapies for peripheral artery disease. Circulation. 2016;134:2008–2027.
12.
KatsanosKKitrouPSpiliopoulosS. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23:851–863.
13.
Biondi-ZoccaiGGSangiorgiGLotrionteM. Infragenicular stent implantation for below-the-knee atherosclerotic disease: clinical evidence from an international collaborative meta-analysis on 640 patients. J Endovasc Ther. 2009;16:251–260.
14.
Biondi-ZoccaiGSangiorgiGD’AscenzoF. Drug-eluting balloons for peripheral artery disease: a meta-analysis of 7 randomized clinical trials and 643 patients. Int J Cardiol. 2013;168:570–571.
15.
GiordanoAPeruzziMFratiG. Commentary: Identifying the best device for infrapopliteal revascularization through quantitative evidence synthesis. J Endovasc Ther. 2016;23:864–866.
16.
GiordanoAMessinaSPolimenoM. A registry on distal popliteal and infrapopliteal revascularization with coronary drug-eluting stents. J Cardiovasc Med (Hagerstown). 2014;15:822–827.
17.
GiordanoAFerraroPCorcioneN. Endovascular therapy for infrainguinal artery disease with coronary devices: a retrospective observational study comparing drug-eluting stents versus bioresorbable vascular scaffolds. Angiology. 2017;68:59–66.
18.
FischmanDSavageMZalewskiA. Overview of the Palmaz-Schatz stent. J Invasive Cardiol. 1991;3:75–84.
19.
SerruysPWStraussBHde FeyterP. The Wallstent: a self-expanding stent. J Invasive Cardiol. 1991;3:127–134.
20.
KudagiVSWhiteCJ.Endovascular stents: a review of their use in peripheral arterial disease. Am J Cardiovasc Drugs. 2013;13:199–212.
21.
KarnabatidisDKatsanosKSpiliopoulosS. Incidence, anatomical location, and clinical significance of compressions and fractures in infrapopliteal balloon-expandable metal stents. J Endovasc Ther. 2009;16:15–22.
22.
IqbalJGunnJSerruysPW.Coronary stents: historical development, current status and future directions. Br Med Bull. 2013;106:193–211.
23.
DakeMDAnselGMJaffMR; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.
van GeunsRJYetginTLa MannaA. STENTYS self-apposing sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial. EuroIntervention. 2016;11:e1267–e1274.
26.
StoneGWGaoRKimuraT. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387:1277–1289.
27.
AbizaidARibamar CostaJJr.The unmet needs: How future technologies will address current limitations of bioresorbable scaffold technology. Catheter Cardiovasc Interv. 2016;88:54–59.
28.
GiordanoACorcioneNPolimenoM. No surprising forward jump when deploying a self-expandable stent: two cases exploiting the combination of Emboshield Nav6 BareWire and Stentys devices. Int J Cardiol2013;168:3079–3081.
29.
BosiersMCallaertJKeirseK. One-year outcomes of the paclitaxel-eluting, self-expanding Stentys stent system in the treatment of infrapopliteal lesions in patients with critical limb ischemia. J Endovasc Ther. 2017;24:311–316.
